The Pharma Letter M&A roundup - June 2023

6 July 2023

Big pharma companies Novartis (NOVN: VX) and Eli Lilly (NYSE: LLY) announced major deals during a big-spending month in mergers and acquisitions.

Other big firms and smaller players from the industry also announced acquisitions as the rate of spending in the sector continued to outpace the previous two years.

A major reason that 2023 is so far ahead of 2021 and 2022 is the $43 billion Pfizer (NYSE: PFE) buy of Seagen (Nasdaq: SGEN), which continues to make the US pharma giant by far the biggest spender in pharma acquisitions over the year, the the deal has yet to gain competition authority clearance..

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK